Unlocking the power

of complex proteins for

future therapies

Unlocking the power

of complex proteins for

future therapies

Mission

We develop drug candidates to advance into the clinic with pharmaceutical partners

New solutions and new therapies need new avenues to reach them. The age of cells producing biological compounds has achieved a lot for human medicine, but its means are coming to an end. A step change in technology is required to unleash the potential of molecules we didn’t dream we would discover – or be able to create if we did.

ELEVA is opening this realm of unprecedented therapies with the help of an inconspicuous but incredibly efficient tool: Bryophyta, more commonly known as moss. This ancient organism holds the key to the therapies of the future. Moss plants are not only able to produce the most complex and demanding proteins; with their unique characteristics, they virtually invite easy, stable engineering and reliable output.

What we offer

How Eleva can change your world

We have harnessed the moss platform’s outstanding features to create candidates and take them to clinical stages, ready for a bright future. Be our clinical partner to develop unprecedented candidates into the therapies that will turn around countless patient’s lives.

  • Are you looking for a partner with an asset that might be the key to a revolutionary treatment?
  • Are you struggling with a difficult protein?
  • Are you toying with a revolutionary toxin that targets just the right cells?

Join us and our moss cells to unleash opportunities never imagined before, based on a platform that surpasses the capacities of all other cell lines used to date.

Talk to us if you are looking at producing

  • Antibodies
  • Biobetters
  • LSD enzymes
  • Fusion toxins
  • Virus-like particles/vaccines
  • Any complex, difficult protein
  • Efficient and effective glycosylation
Technology

Everything you expect from cell line development – yet without the problems

Tailored glycosylation
Tailored glycosylation

Tailored glycosylation

Wherever glycosylation is a problem, moss is your solution. Moss has no core α-1,6 fucose to begin with. Any other glycans can be modified to the desired effect, be it by knocking certain genes out or inserting the necessary transferases. No allergens, more power. We are experts in moss glycodesign, “humanizing” the molecules’ glycostructure. We have demonstrated excellent organ uptake, even in clinical studies. Our “glyco platform” is just what you were hoping for.

Flexible genetic engineering

Moss is haploid by nature and boasts its very own pair of DNA scissors. Engineering its genome is easy. Make any changes you like, wherever you need them: change one nucleotide or a thousand, one site or many. We don’t even need markers to check the correct modifications, just PCR. The moss production system is based on an intact organism, not artificial cell cultures. This guarantees exceptionally reliable and stable modifications.

Pathogen-free processing

The lack of animal pathogens means antibiotics are not necessary. Not only does this ensure constant supply with no threat of contamination. It also eliminates the time and cost-consuming process of removing pathogens in the first place, and ticks another box for regulatory approval.

fusion toxin production

Moss can produce any desired toxin or toxin fusion protein, be it by natural resistance or by means of a genetically engineered, resistant platform. Moss cells hardly leak any toxins into the cytosol, but secrete them – making harvesting easy. Impossible in any other cells!

Business model​

At Eleva ...

We develop clinical assets in partnership with pharmaceutical companies

… we develop early clinical assets in partnership with pharmaceutical companies

We unlock the potential of difficult compounds that have so far failed to get expressed

… we unlock the potential of difficult compounds that have so far failed to get expressed

We explore unusual opportunities in other promising fields

… we explore unusual opportunities in other promising fields

We have successfully developed enzymes and other proteins into clinical stages and continue to scout for promising compounds. This results in a plethora of opportunities. Whilst our technology platform remains the property of Eleva, new individual assets will be developed in cooperation with pharmaceutical partners. Each of such partnerships will be taken into a newly formed subsidiary. This allows the partners to focus on the respective indication.

Our Pipeline

We are inviting pharmaceutical partners to take all current and future candidates to clinical success.

Indication

 

C3 glomerulopathy (C3G)

 

Complement disorders

 

Complement disorders

Research

Preclinical

Phase I

Phase II

Therapies for complement disorders
Compleva FH (natural complement regulator)
Compleva MFHR1 (novel multi-level complement regulator)
Compleva FHL (natural complement regulator)
Therapies for complement disorders

Indication​ C3 glomerulopathy (C3G)

Compleva FH (natural complement regulator)

Research

Preclinical

Phase I

Phase II

Indication complement disorders

Compleva MFHR1 (novel multi-level complement regulator)

Research

Preclinical

Phase I

Phase II

Indication complement disorders

Compleva FHL (natural complement regulator)

Research

Preclinical

Phase I

Phase II

 

Fabry disease

 

Pompe disease

Enzyme replacement therapies

Repleva AGAL (glyco-improved Fabry-ERT)

Repleva GAA (glyco-improved Pompe-ERT)

Enzyme replacement therapies

Indication Fabry disease

Repleva AGAL (glyco-improved Fabry-ERT)

Research

Preclinical

Phase I

Phase II

Indication Pompe disease

Repleva GAA (glyco-improved Pompe-ERT)

Research

Preclinical

Phase I

Phase II

News

Greenovation transforms into Eleva

May 18, 2020

Greenovation is launching its supreme moss-based development platform with a new business model and is transforming into a new company, Eleva.

READ MORE

Eleva’s drug candidate to be examined for use in Covid-19 treatment

June 3, 2020

Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through pre-clinical stages.

READ MORE

Contact

We look forward to hearing from you! 

eleva GmbH
Hans-Bunte-Str. 19
79108 Freiburg
Germany

Phone: +49 761 470 99 0
hello@elevabiologics.com

I consent to the processing of my personal data for the purpose of establishing contact in accordance with Article 6 paragraph 1 lit a of the Basic Data Protection Regulation (DSGVO). I consent to the processing of my personal data for the purpose of establishing contact in accordance with Article 6 paragraph 1 letter a of the Basic Data Protection Regulation (DSGVO).

In accordance with Article 13 of the Basic Data Protection Regulation (DSGVO), we would like to provide you with comprehensive information about the processing of your personal data. You can read all relevant information in our data protection policy.

eleva Newsletter